312 related articles for article (PubMed ID: 33661931)
1. Overcoming TRAIL-resistance by sensitizing prostate cancer 3D spheroids with taxanes.
Grayson KA; Jyotsana N; Ortiz-Otero N; King MR
PLoS One; 2021; 16(3):e0246733. PubMed ID: 33661931
[TBL] [Abstract][Full Text] [Related]
2. Taxanes Sensitize Prostate Cancer Cells to TRAIL-Induced Apoptotic Synergy via Endoplasmic Reticulum Stress.
Grayson KA; Hope JM; Wang W; Reinhart-King CA; King MR
Mol Cancer Ther; 2021 May; 20(5):833-845. PubMed ID: 33632873
[TBL] [Abstract][Full Text] [Related]
3. TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
Chandrasekaran S; Marshall JR; Messing JA; Hsu JW; King MR
PLoS One; 2014; 9(10):e111487. PubMed ID: 25343626
[TBL] [Abstract][Full Text] [Related]
4. Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes.
Ríos-Colón L; Cajigas-Du Ross CK; Basu A; Elix C; Alicea-Polanco I; Sanchez TW; Radhakrishnan V; Chen CS; Casiano CA
Oncotarget; 2017 Apr; 8(15):24915-24931. PubMed ID: 28212536
[TBL] [Abstract][Full Text] [Related]
5. Effects of docetaxel on metastatic prostate (DU-145) carcinoma cells cultured as 2D monolayers and 3D multicellular tumor spheroids.
Fujiike AY; de Oliveira LCB; Ribeiro DL; Pereira ÉR; Okuyama NCM; Dos Santos AGP; de Syllos Cólus IM; Serpeloni JM
J Toxicol Environ Health A; 2024 Mar; 87(6):227-244. PubMed ID: 38095149
[TBL] [Abstract][Full Text] [Related]
6. Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroids.
Stöhr D; Schmid JO; Beigl TB; Mack A; Maichl DS; Cao K; Budai B; Fullstone G; Kontermann RE; Mürdter TE; Tait SWG; Hagenlocher C; Pollak N; Scheurich P; Rehm M
Cell Death Differ; 2020 Nov; 27(11):3037-3052. PubMed ID: 32433558
[TBL] [Abstract][Full Text] [Related]
7. Cancer-associated fibroblasts promote prostate tumor growth and progression through upregulation of cholesterol and steroid biosynthesis.
Neuwirt H; Bouchal J; Kharaishvili G; Ploner C; Jöhrer K; Pitterl F; Weber A; Klocker H; Eder IE
Cell Commun Signal; 2020 Jan; 18(1):11. PubMed ID: 31980029
[TBL] [Abstract][Full Text] [Related]
8. Pleiotropic effects of probenecid on three-dimensional cultures of prostate cancer cells.
Uwada J; Mukai S; Terada N; Nakazawa H; Islam MS; Nagai T; Fujii M; Yamasaki K; Taniguchi T; Kamoto T; Yazawa T
Life Sci; 2021 Aug; 278():119554. PubMed ID: 33932444
[TBL] [Abstract][Full Text] [Related]
9. Combination Treatment with Orlistat-Containing Nanoparticles and Taxanes Is Synergistic and Enhances Microtubule Stability in Taxane-Resistant Prostate Cancer Cells.
Souchek JJ; Davis AL; Hill TK; Holmes MB; Qi B; Singh PK; Kridel SJ; Mohs AM
Mol Cancer Ther; 2017 Sep; 16(9):1819-1830. PubMed ID: 28615298
[TBL] [Abstract][Full Text] [Related]
10. Clusterin mediates TRAIL resistance in prostate tumor cells.
Sallman DA; Chen X; Zhong B; Gilvary DL; Zhou J; Wei S; Djeu JY
Mol Cancer Ther; 2007 Nov; 6(11):2938-47. PubMed ID: 18025278
[TBL] [Abstract][Full Text] [Related]
11. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
[TBL] [Abstract][Full Text] [Related]
12. Cancer-Associated Fibroblasts Modify the Response of Prostate Cancer Cells to Androgen and Anti-Androgens in Three-Dimensional Spheroid Culture.
Eder T; Weber A; Neuwirt H; Grünbacher G; Ploner C; Klocker H; Sampson N; Eder IE
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598125
[TBL] [Abstract][Full Text] [Related]
13. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
Frankel A; Man S; Elliott P; Adams J; Kerbel RS
Clin Cancer Res; 2000 Sep; 6(9):3719-28. PubMed ID: 10999766
[TBL] [Abstract][Full Text] [Related]
14. Topoisomerase II alpha inhibition can overcome taxane-resistant prostate cancer through DNA repair pathways.
Hongo H; Kosaka T; Suzuki Y; Mikami S; Fukada J; Oya M
Sci Rep; 2021 Nov; 11(1):22284. PubMed ID: 34782700
[TBL] [Abstract][Full Text] [Related]
15. Targeted radiotherapy potentiates the cytotoxicity of a novel anti-human DR5 monoclonal antibody and the adenovirus encoding soluble TRAIL in prostate cancer.
Arafat W; Zhou T; Naoum GE; Buchsbaum DJ
J Egypt Natl Canc Inst; 2015 Dec; 27(4):205-15. PubMed ID: 26385392
[TBL] [Abstract][Full Text] [Related]
16. An antibody against DR4 (TRAIL-R1) in combination with doxorubicin selectively kills malignant but not normal prostate cells.
Voelkel-Johnson C
Cancer Biol Ther; 2003; 2(3):283-90. PubMed ID: 12878867
[TBL] [Abstract][Full Text] [Related]
17. Androgen receptor nuclear localization correlates with AR-V7 mRNA expression in circulating tumor cells (CTCs) from metastatic castration resistance prostate cancer patients.
Worroll D; Galletti G; Gjyrezi A; Nanus DM; Tagawa ST; Giannakakou P
Phys Biol; 2019 Mar; 16(3):036003. PubMed ID: 30763921
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment of docetaxel enhances TRAIL-mediated apoptosis in prostate cancer cells.
Yoo J; Park SS; Lee YJ
J Cell Biochem; 2008 Aug; 104(5):1636-46. PubMed ID: 18404675
[TBL] [Abstract][Full Text] [Related]
19. DNA-PKc inhibition overcomes taxane resistance by promoting taxane-induced DNA damage in prostate cancer cells.
Chao OS; Goodman OB
Prostate; 2021 Oct; 81(14):1032-1048. PubMed ID: 34297853
[TBL] [Abstract][Full Text] [Related]
20. The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer.
Chitcholtan K; Sykes PH; Evans JJ
J Transl Med; 2012 Mar; 10():38. PubMed ID: 22394685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
